When should an alternative agent to vancomycin be considered for MRSA infections?

Let's Talk MRSA: 20 Frequently Asked Questions
21/11/2010

Listen "When should an alternative agent to vancomycin be considered for MRSA infections? "

Descargar episodio Ver en sitio original

Episode Synopsis


In this Episode, Dr. Scott T. Micek from Barnes-Jewish Hospital in St. Louis, Missouri provides insights
on when an alternative agent to vancomycin should be considered for MRSA infections.

More episodes of the podcast Let's Talk MRSA: 20 Frequently Asked Questions

What are the short- and long-term challenges as well as advancements that will impact the management of patients with MRSA infections? 13/02/2011
How can we prevent the spread of MRSA in the hospital? 06/02/2011
Is there a role for OPAT in the management of patients with MRSA infections? 30/01/2011
Can we determine the appropriate duration of therapy for MRSA infections? 23/01/2011
What stewardship tactics can be applied to the management of MRSA infections? 16/01/2011
Can we differentiate among newer agents for MRSA bacteremia and endocarditis? 09/01/2011
How should clinicians manage MRSA bacteremia and infective endocarditis? 02/01/2011
How can primary care physicians manage community-associated MRSA pneumonia? 26/12/2010
What is the optimal treatment for MRSA nosocomial pneumonia? 19/12/2010
What are the therapeutic options for a complicated skin or skin structure MRSA infection? 12/12/2010
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA